NSE: FERMENTA · BSE: 506414 · ISIN INE225B01021
Fermenta Biotech Limited stock analysis
Fermenta Biotech Limited ranks #1736 in the TickerSutra evidence-ranked universe with a score of 51/100 and 95% data confidence. The latest captured fundamentals show ROCE of 20.6%, quarterly sales growth of -10.6% and quarterly profit growth of -55.4%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 20.6%
- Low debt/equity of 0.28×
- Strong CFO/EBITDA of 0.92×
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- Operating margin has compressed materially
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹397cr | ₹62cr | ₹15cr | 16.0% |
| 2023 | ₹349cr | ₹18cr | ₹-53cr | 5.0% |
| 2024 | ₹335cr | ₹28cr | ₹-24cr | 8.0% |
| 2025 | ₹468cr | ₹115cr | ₹76cr | 25.0% |
| 2026 | ₹523cr | ₹101cr | ₹70cr | 19.0% |
| TTM | ₹511cr | ₹90cr | ₹58cr | 18.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Fermenta Biotech Limited has informed the Exchange about Schedule of investor(s) meeting to be held on October 05, 2026.
RoutineTrading WindowBSE · 29 Sept 2026Fermenta Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
RoutineAnalysts/Institutional Investor Meet/Con. Call UpdatesNSE · 22 Sept 2026Fermenta Biotech Limited has informed the Exchange about Schedule of investor(s) meeting.
MANAGEMENT COMMENTARY
Signals from filed documents
Employee, sales and administrative costs rose modestly as the business added capacity and widened market development, keeping the margin profile anchored while funding growth. Cost Components FY26 Key Drivers Raw Materials Employee Cost Manufacturing Expenses Sales & Marketing Administrative Finance Costs Improved sourcing mix Capacity expansion adds heads Operating leverage on higher volumes Wider market development
Manufacturing leverage offset selective cost investment Finance costs eased on continued deleveraging Margins protected while funding growth Cost Discipline Anchors Margins The cost base held broadly stable as a share of revenue. Manufacturing expenses fell to 12% on operating leverage from higher volumes, and finance costs eased to 2% on continued deleveraging. Raw materials edged down to 37% on an improved sourcing
Manufacturing leverage offset selective cost investment Finance costs eased on continued deleveraging Margins protected while funding growth Cost Discipline Anchors Margins The cost base held broadly stable as a share of revenue. Manufacturing expenses fell to 12% on operating leverage from higher volumes, and finance costs eased to 2% on continued deleveraging. Raw materials edged down to 37% on an improved sourcing
Also approved by WFP Our dedicated Premix plant has also received GAIN certification 100+ scientists & engineers 75+ years of expertise 15+ key certifications 400+ global customers Management Discussion and Analysis Annual Report 2025-26 | 17 Note: Maps are not to scale. Seventy-five years of accumulated process know-how, a core of scientists and engineers, and deep expertise in complex and green chemistry are what turn
To our employees: thank you for your excellence and hard work. To our customers, regulators, and banking and supply partners: thank you for the trust. To the Chairman and the Board: thank you for the room to execute.
Plant-Source and Natural Actives: Clean, plant-source and organic ingredients, including plant-source Vitamin D3 Biocatalysis and Green Chemistry: Enzyme-led, lower-footprint routes to high-value molecules Advanced Delivery: Technologies that enhance nutrient and active bioavailability Fermenta anticipates and responds to these trends through Innovation Chemistry, creating lasting value with science-validated product
The differentiated Chemistry business more than doubled its revenue since FY23 to 15% of the total, with Green Chemistry alone more than doubling year-on-year. Also approved by WFP Our dedicated Premix plant has also received GAIN certification 100+ scientists & engineers 75+ years of expertise 15+ key certifications 400+ global customers Management Discussion and Analysis Annual Report 2025-26 | 17 Note: Maps are not
Geographical Revenue Mix A strong global presence, with revenue contributions balanced across India, Europe, North America, and other regions The top 10 make up a moderate42%of revenue; the remaining 58% is spread across a broad base of mid-market accounts, with only 2 customers above 5% The mid-market tier has widened from 56 to 68 accounts, deepening the base Excl. Value Unlocking of revenue from the largest custom
Gratitude The legacy of this Company has been carried by the Datla family for 75 years across three generations and held together at the operating level by a culture of honesty, candour, and trust. Fermenta has never had a regulatory observation against any of its manufacturing facilities in any geography we serve. That fact, although mentioned rarely, is in my view an accurate measure of what this Company represents
Whether it also displa ys official news releases: Yes g. P resentations made to institutional investors or to analysts: Yes, the same are also uploaded on BSE website (www. bseindia.com) and the Company’s website (www.fermentabiotech.com) as per statutory requirements.
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…